New study hopes ilaris can tame rare inflammatory disorder
NCT ID NCT07598422
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study will test the drug Ilaris (canakinumab) in about 5 people with Schnitzler's syndrome, a rare condition that causes hives, fever, joint pain, and fatigue. The goal is to see if Ilaris can reduce or stop these symptoms. Participants will be followed for up to 48 weeks to check how well the drug works and if it causes any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHNITZLER SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.